Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 2.02
CSP Inc. issued a press release on August 14, 2026, announcing financial results for the third quarter of fiscal year 2026 ended June 30, 2026. The disclosure includes detailed quarterly and nine-month financial statements (sales, gross profit, net loss per share), management commentary on business performance, and forward-looking guidance. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial condition and operational performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-14
Item 2.02
Reading International issued a press release on August 14, 2026 announcing Q2 2026 financial results, including total revenues of $66.9 million (11% increase YoY), operating income of $7.5 million (159% improvement), and net income of $2.3 million. The release highlights the highest second quarter revenues since pre-pandemic and includes detailed segment performance, balance sheet metrics, and forward-looking guidance. This is a standard quarterly earnings release disclosure under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 2.02
Cumulus Media issued a press release on August 14, 2026, announcing operating results for the three and six months ended June 30, 2026, including net revenue of $167.9 million and $332.4 million respectively, net losses of $9.2 million and $26.1 million, and Adjusted EBITDA of $16.0 million and $18.7 million. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for earnings releases. The disclosure is material as it reports quarterly financial results showing revenue declines of 9.7% and 11.0% year-over-year.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-14
EX-99.1
This is a quarterly earnings release disclosing Q2 2026 financial and operational results for Americas Gold and Silver Corporation. The exhibit reports consolidated net revenue of $46 million (71% increase YoY), silver production of 665,000 ounces, net loss of $5.0 million, and adjusted EBITDA of $12.0 million, along with detailed operational metrics and full-year 2026 guidance. The document explicitly states "reports consolidated financial and operational results for the quarter ended June 30, 2026" and includes management commentary from the CEO, making it a standard quarterly earnings announcement material to investors.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-14
EX-99.1
This is a press release announcing Q2 2026 financial results for Mako Mining Corp., disclosing record revenue of $62.6 million, Adjusted EBITDA of $31.7 million, net income of $13.9 million ($0.16/share), and operational metrics for the three months ended June 30, 2026. The document explicitly states "Mako Mining Reports Q2 2026 Financial Results" and provides detailed financial and operational highlights typical of a quarterly earnings announcement. Material to investors as it reports significant financial performance and profitability metrics.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-14
Item 2.02
Leatt Corporation disclosed financial results for Q2 2026 and the first six months of 2026, reporting Q2 revenues of $16.39 million (up 1% YoY), net income of $908,989, and six-month revenues of $35.90 million (up 14% YoY) with net income of $2.68 million (up 19% YoY).
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 2.02
Sphere 3D Corp. disclosed Q2 2026 financial results for the quarter ended June 30, 2026, reporting revenue of $2.5 million and a net loss of $13.8 million, including material impairment charges totaling $7.6 million, via press release furnished on August 14, 2026.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-14
EX-99.1
This is a press release announcing Largo's Q2 2026 financial results, including revenues of $44.0 million (up 68.5%), Adjusted EBITDA of $2.7 million, and vanadium production of 2,900 tonnes (up 28.5%). The release explicitly states "Largo Reports Q2 2026 Financial Results" and provides comprehensive quarterly financial and operational metrics. While the release also discusses subsequent events (Defense Logistics Agency order, copper-PGM production initiation), the primary disclosure is the quarterly earnings announcement, which is material to investors assessing the company's financial performance and operational trajectory.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-14
EX-99.5
This is a press release dated August 12, 2026, announcing Denison's "Financial and Operational Results for Q2 2026." The exhibit discloses condensed consolidated financial statements and MD&A for the three and six months ended June 30, 2026, filed with SEDAR+, EDGAR, and the company website. The release highlights Q2 financial results including uranium sales generating $91.6 million in gross proceeds and a $64.1 million realized gain, along with operational progress at the Phoenix ISR uranium mine. This is a discrete earnings announcement, not a periodic financial report itself.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 2.02
This is a clear earnings release disclosing Lifeloc's operating results for the quarter ended June 30, 2026. The Item 2.02 filing announces quarterly net revenue of $2.445 million and a net loss of $(134) thousand, with detailed financial statements (balance sheet, income statement, cash flows, and equity changes) attached as Exhibit 99.1. The press release explicitly states "Lifeloc Reports Second Quarter 2026 Results" and provides comparative results to the prior year period, which is the hallmark of an earnings disclosure.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-14
EX-99.1
This is a press release announcing RLX Technology's unaudited second quarter 2026 financial results, including net revenues of RMB1,010.5 million (up 14.8% YoY), gross margin of 35.4%, and net income of RMB222.0 million. The document explicitly states "RLX Technology Announces Unaudited Second Quarter 2026 Financial Results" and provides comprehensive quarterly financial metrics, management commentary, and forward guidance. This is a discrete earnings announcement, not a periodic financial report filing.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-14
EX-99.1
This exhibit is a press release announcing CASI Pharmaceuticals' first-half 2026 business and financial results, dated August 14, 2026. It discloses revenues of $9.8 million, a net loss of $20.0 million, cash position of $3.8 million, and includes unaudited condensed consolidated balance sheets and statements of operations. The disclosure is material as it reports interim financial performance and includes significant operational updates (clinical trial progress, Nasdaq delisting, OTCQB quotation, and a $15 million convertible note financing).
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 2.02
This is a standard quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02. The press release discloses financial results including R&D expenses ($4.0M vs $5.8M YoY), G&A expenses ($2.6M vs $3.1M YoY), net loss ($6.5M vs net income of $4.2M in prior year), and EPS of $(0.69), along with consolidated balance sheets and statements of operations. The filing also includes material business updates on TTI-109 clinical progress and UC indication selection, which are integral to the earnings announcement.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 2.02
The filing discloses Outlook Therapeutics' third quarter fiscal year 2026 financial results (ended June 30, 2026), including net loss of $20.3 million ($0.15 per share) and adjusted net loss of $10.9 million ($0.09 per share). The press release in Exhibit 99.1 is a standard earnings announcement that reports quarterly financial results alongside a business update on the FDA approval of LYTENAVA and commercial launch preparations. This is a material earnings disclosure under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 2.02
This is a classic earnings release disclosure under Item 2.02. The company announced financial results for the fiscal first quarter ended June 30, 2026, including R&D expenses ($49.3M), SG&A expenses ($19.0M), and net loss ($69.8M), along with balance sheet data and cash position. The news release is furnished as Exhibit 99.1 and includes material corporate updates (FDA approval of TUDRIQEV, executive appointment, financing completion). This is material to investors as it provides quarterly financial performance and significant operational milestones.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-14
This is a press release dated August 13, 2026 announcing Turkcell's second quarter 2026 financial results. The document contains consolidated financial statements (revenue, EBITDA, EBIT, net income), operational metrics (subscriber additions, churn rates), and forward-looking guidance for full-year 2026. The enclosure explicitly states it is "a press release dated August 13, 2026 announcing the release of the registrant's second quarter 2026 results," which is the hallmark of an earnings release disclosure.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-14
EX-99.1
This is an announcement that JinkoSolar will release its unaudited financial results for Q2 2026 (ended June 30, 2026) on August 26, 2026, accompanied by a management earnings conference call. Although the actual results are not disclosed in this exhibit, the announcement of the forthcoming earnings release and conference call is the standard form of earnings disclosure for public companies and would materially affect investor assessment of the registrant's financial performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-14
Item 2.02
This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02 Results of Operations and Financial Condition. The press release (Exhibit 99.1) discloses quarterly financial results including balance sheet, statement of operations, net loss per share ($0.40 basic and diluted), and key operational metrics. The filing explicitly states "issued a press release reporting earnings for the quarter ended June 30, 2026."
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 2.02
This is a standard earnings release disclosing Q2 2026 financial results for Quoin Pharmaceuticals. The filing explicitly states "On August 14, 2026 Quoin Pharmaceuticals Ltd. (the 'Company') issued a press release announcing its financial results for the quarter ended June 30, 2026," with the press release furnished as Exhibit 99.1. The exhibit contains consolidated balance sheets, statements of operations, and loss per ADS metrics for the periods ended June 30, 2026 and 2025, along with operational highlights. This is a material disclosure affecting investor assessment of the company's financial condition and operational progress.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 2.02
This is a standard quarterly earnings release for Q2 2026 ended June 30, 2026, disclosing financial results including net loss of $3.9 million, cash position of $0.2 million, and operating expenses. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings announcements. The filing includes consolidated balance sheet and comprehensive loss statements for the period.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 7.01
Traws Pharma disclosed Q2 2026 financial results via press release on August 14, 2026, reporting zero revenue, R&D expenses of $1.1M, G&A expenses of $3.5M, and a net loss of $3.0M for the quarter ($0.16 per share), with cash and equivalents of $5.0M as of June 30, 2026.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 8.01
The filing discloses quarterly and six-month financial results for the periods ended June 30, 2026, including net sales, operating losses, and net income/loss figures. The press release attached as Exhibit 99 announces these results, which is the hallmark of an earnings release disclosure under Item 8.01. The results show material declines in revenue (Q2 2026: $7.2M vs. Q2 2025: $10.4M) and significant operating losses, making this material to investors.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-14
Item 2.02
This is a straightforward earnings release for Q2 2026 ended June 30, 2026. The press release discloses key financial metrics including revenue of $7.0M (up 22% YoY), return to positive Adjusted EBITDA of $0.4M, and improved cash position exceeding $3M. The filing explicitly states the press release is being furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 2.02
This is a classic Item 2.02 earnings release. Galectin Therapeutics issued a press release on August 14, 2026 announcing financial results for the six months ended June 30, 2026, including condensed consolidated statements of operations and balance sheet data. The filing explicitly states the company "issued a press release announcing its results of operations and financial condition" and incorporates the press release by reference as Exhibit 99.1, which contains detailed quarterly financial highlights, net loss figures, and cash position disclosures typical of earnings announcements.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 2.02
This is a clear earnings release disclosing Sinda Ltd.'s financial results for the quarter ended June 30, 2026, including a net loss of $16.6 million and operational highlights. The press release is furnished as Exhibit 99.1 to the 8-K Item 2.02 (Results of Operations and Financial Condition), which is the standard vehicle for earnings announcements. The disclosure is material as it reports the company's first quarter as a public company following its June 2026 IPO, including capital raised ($331.3 million gross proceeds) and operational progress on exploration and development activities.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 2.02
This is a standard earnings release disclosing quarterly and six-month financial results for the period ended June 30, 2026, including sales, operating expenses, net loss, and per-share metrics. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings announcements. The disclosure includes detailed financial statements and is material to investors assessing the company's operational performance and financial condition.
View raw filing on EDGAR →
6-K
Earnings release
confidence 92%
filed 2026-08-14
EX-99.1
This is a press release announcing Q2 2026 financial and operational results for Quantum BioPharma, including cash position (US$9.5M), balance sheet metrics, reduced operating expenses (53% decrease YoY), and a material regulatory milestone—FDA approval to proceed with the Lucid-MS Phase 2 clinical trial. The disclosure of quarterly financial results combined with the pivotal clinical development milestone makes this a material earnings release that would affect a reasonable investor's assessment of the company's financial health and pipeline progress.
View raw filing on EDGAR →
6-K
Earnings release
confidence 92%
filed 2026-08-14
EX-99.1
This is a press release announcing that Evaxion will report its second quarter 2026 financial results on August 20, 2026, with a conference call and webcast. Although the actual results are not disclosed in this exhibit, the announcement of an upcoming earnings report and business update is a standard earnings-release disclosure. The filing date (August 14) precedes the results announcement (August 20), making this a pre-announcement notice that qualifies as an earnings-related disclosure material to investors.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-14
Item 2.02
This is a clear earnings release disclosing Q2 2026 financial results for Axe Compute Inc., including revenue of $3.2 million, net loss of $17.2 million, and Adjusted EBITDA of ($4.9 million). The press release is attached as Exhibit 99.1 and filed under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing also includes condensed consolidated balance sheets, statements of net loss, and cash flow statements for the periods ended June 30, 2026.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 2.02
BeyondSpring issued a press release on August 14, 2026 announcing its financial results for the quarter ended June 30, 2026, with detailed condensed consolidated balance sheets and statements of comprehensive income (loss) for both quarterly and year-to-date periods. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes R&D and G&A expense comparisons, net loss figures, cash position, and per-share data, all characteristic of a quarterly earnings announcement.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 2.02
This is a classic earnings release disclosure under Item 2.02. The filing announces "financial results for the second quarter and six months ended June 30, 2026" with detailed financial metrics (R&D expenses, G&A expenses, net loss) and a press release attached as Exhibit 99.1. The disclosure includes both financial results and material business updates (Phase 2/3 clinical trial initiation, regulatory approvals, financing activities), making it material to investors assessing the company's progress and financial condition.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 2.02
Lifeward Ltd. announced Q2 2026 financial results (ended June 30, 2026) showing revenue of $6.6 million (16% increase), operating loss of $4.2 million, and net loss of $11.5 million per share, with detailed financial statements and management commentary on commercial execution and balance sheet strengthening.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-14
EX-99.1
This is a press release announcing Melco Resorts' unaudited financial results for the second quarter of 2026, dated August 13, 2026. It discloses total operating revenues of US$1.25 billion (down 6% YoY), operating income of US$127.8 million, net income of US$22.7 million (US$0.06 per ADS), and Adjusted Property EBITDA of US$303.8 million, along with detailed segment performance metrics. This is a classic earnings release disclosing quarterly financial results, material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-14
This is a second quarter 2026 earnings release disclosing unaudited financial results for the period ended June 30, 2026. The document presents consolidated net loss of $2.9 million for Q2 2026 (versus net income of $13.7 million in Q2 2025), revenue decline of 65% year-over-year, and detailed financial position data. The filing includes the "SECOND QUARTER NEWS RELEASE" header and comprehensive financial tables and management discussion of results, which are hallmarks of an earnings announcement. Material to investors as it shows significant deterioration in profitability and revenue.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-14
EX-99.1
This exhibit is a press release announcing unaudited financial results for the second quarter of 2026, disclosing total operating revenues of US$164.6 million (down from US$190.1 million in Q2 2025), operating income of US$15.0 million (down from US$23.1 million), and a net loss of US$15.6 million per ADS (compared to US$3.7 million loss in Q2 2025). The document includes condensed consolidated statements of operations, balance sheets, and reconciliations of non-GAAP measures, all hallmarks of a quarterly earnings release. Material to investors as it discloses significant revenue decline and increased losses.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 2.02
The filing discloses quarterly and six-month financial results for PowerCompute, Inc. for the periods ended June 30, 2026, presented via a press release (Exhibit 99.1) attached to Item 2.02. The press release includes consolidated statements of operations, balance sheets, and cash flows, along with management commentary on financial performance, operational highlights, and strategic initiatives. This is a standard earnings release disclosure.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 2.02
Neumora disclosed second quarter 2026 financial results, including R&D expenses of $29.3M, G&A expenses of $12.9M, net loss of $43.1M, and cash position of $116.8M, with forward-looking guidance on cash runway through Q3 2027.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 2.02
TuHURA Biosciences issued a press release on August 14, 2026, reporting financial results for the second quarter ended June 30, 2026, including R&D expenses ($6.6M vs. $4.9M YoY), G&A expenses ($2.1M vs. $1.9M YoY), cash position ($1.0M), and operating cash flows. The disclosure is a standard quarterly earnings release with financial metrics and a corporate update, filed under Item 2.02 and attached as Exhibit 99.1.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 2.02
PMV Pharmaceuticals issued a press release on August 14, 2026, announcing its financial results for the second quarter ended June 30, 2026. The disclosure includes condensed consolidated balance sheets, statements of operations and comprehensive loss, and detailed financial metrics (net loss of $18.1 million for Q2 2026, R&D expenses of $14.7 million, cash position of $79.4 million). This is a standard quarterly earnings release with full financial statements attached as Exhibit 99.1, typical of Item 2.02 disclosures.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 2.02
This is a press release announcing Aptevo's financial results for the quarter ended June 30, 2026, filed under Item 2.02 (Results of Operations and Financial Condition). The disclosure includes Q2 2026 financial position (cash and cash equivalents of $9.8 million) and operational updates on clinical progress, executive appointments, and strategic collaborations. The Item 2.02 classification and attached press release (Exhibit 99.1) are the hallmarks of an earnings release disclosure.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-14
Item 2.02
Item 2.02 discloses Suncrete's Q2 2026 financial results via a press release (Exhibit 99.1) announcing revenue of $97.2 million (up 146% YoY), net loss of $37.1 million, and adjusted EBITDA of $13.5 million, along with updated 2026 full-year guidance. This is a standard earnings release disclosure material to investors assessing the company's financial performance and outlook.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 2.02
This is a quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02 Results of Operations and Financial Condition. The press release (Exhibit 99.1) discloses financial results including R&D expense ($5.5M), G&A expense ($16.6M), and net loss ($75.5M), along with cash position ($116M) and operational highlights. The disclosure is material as it reports significant financial results and strategic developments including the completed Orphai acquisition and private placement financing.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-14
Item 2.02
This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed on August 14, 2026. The Item 2.02 disclosure explicitly states "On August 13, 2026, Rank One Computing Corporation reported its financial results for the quarter ended June 30, 2026" with a press release attached as Exhibit 99.1. The press release contains detailed financial results including revenue ($5.1M), gross margin (90%), net loss ($0.8M), and EPS ($-0.04), along with business highlights and forward guidance—all hallmarks of a quarterly earnings announcement material to investors.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-14
Item 2.02
This is a clear earnings release disclosing Presurance Holdings' second quarter and six-month 2026 financial results. The filing explicitly states "On August 12, 2026, Presurance Holdings, Inc. (the "Company") publicly announced results for the second quarter of 2026" with a news release attached as Exhibit 99.1. The release includes comprehensive financial highlights (net income doubled to $5.2M, combined ratio improved to 86.4%), detailed segment performance, and reconciliations of non-GAAP measures—all hallmarks of a quarterly earnings announcement. Material to investors as it demonstrates significant operational improvement under new leadership.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-14
EX-99.1
This exhibit is a press release announcing Agora, Inc.'s unaudited financial results for the second quarter ended June 30, 2026. It discloses total revenues of $40.4 million (18.0% YoY growth), net income of $2.2 million, and key operating metrics including a 104% Dollar-Based Net Retention Rate. The document includes consolidated financial statements (balance sheet, income statement, and cash flow statement) and forward guidance for Q3 2026 revenues of $41–42 million. This is a classic earnings release event material to investors assessing the company's financial performance and trajectory.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-14
Item 2.02
Item 2.02 discloses Global Crossing Airlines' Q2 2026 financial and operating results through a press release (Exhibit 99.1) and earnings call transcript (Exhibit 99.2). The filing reports quarterly revenue of $62.0M, operating income of $1.4M, net loss of $(1.3)M, and EBITDA of $6.9M, along with operational metrics and management commentary. This is a standard earnings release disclosure material to investors assessing the company's financial performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 2.02
This is a standard earnings release disclosing Cue Biopharma's second quarter 2026 financial results, including revenue of $7.9 million, R&D expenses of $49.0 million, and a net loss of $153.1 million. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing includes condensed consolidated financial statements and detailed discussion of quarterly operating results.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 2.02
LeonaBio issued a press release on August 14, 2026 reporting Q2 2026 financial results, including cash position of $51.1M, R&D expenses of $12.9M, G&A expenses of $6.6M, and net loss of $19.0M ($0.80 per share), along with a business update on Phase 3 ELAINE-3 clinical trial enrollment progress and pipeline programs.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 2.02
This is a clear earnings release disclosing Q2 2026 financial results for Cerenome, Inc. The filing reports operating loss of $9.1 million (vs. $1.5 million in Q2 2025), net loss of $9.0 million or $1.31 per share (vs. net income of $5.2 million in Q2 2025), and cash position of $8.6 million as of June 30, 2026. The press release includes condensed consolidated financial statements and is furnished as Exhibit 99.1 under Item 2.02, which is the standard Item for earnings disclosures. The material deterioration in operating results and significant cash burn are material to investors assessing the company's financial condition.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-14
Item 2.02
The filing discloses Seritage's financial results for the three and six months ended June 30, 2026, including net loss per share of ($0.13) and ($0.69) respectively, cash position, impairment charges, and property sales activity. The press release attached as Exhibit 99.1 is the standard vehicle for quarterly earnings disclosure under Item 2.02, and the financial metrics and operational highlights are material to investors assessing the company's performance and liquidity position.
View raw filing on EDGAR →